TY - JOUR
T1 - Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli
AU - Society of Bacterial Infection and Resistance of Chinese Medical Association
AU - the Expert Committee on Clinical Use of Antimicrobial Agents and Evaluation of Antimicrobial Resistance of the National Health Commission
AU - the Infectious Diseases Society of Chinese Medical Education Association
AU - Zeng, Mei
AU - Xia, Jun
AU - Zong, Zhiyong
AU - Shi, Yi
AU - Ni, Yuxing
AU - Hu, Fupin
AU - Chen, Yijian
AU - Zhuo, Chao
AU - Hu, Bijie
AU - Lv, Xiaoju
AU - Li, Jiabin
AU - Liu, Zhengyin
AU - Zhang, Jing
AU - Yang, Wenjie
AU - Yang, Fan
AU - Yang, Qiwen
AU - Zhou, Hua
AU - Li, Xin
AU - Wang, Jianhua
AU - Li, Yimin
AU - Ren, Jian'an
AU - Chen, Baiyi
AU - Chen, Dechang
AU - Wu, Anhua
AU - Guan, Xiangdong
AU - Qu, Jieming
AU - Wu, Depei
AU - Huang, Xiaojun
AU - Qiu, Haibo
AU - Xu, Yingchun
AU - Yu, Yunsong
AU - Wang, Minggui
N1 - Publisher Copyright:
© 2023
PY - 2023/8
Y1 - 2023/8
N2 - The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group covering clinical infectious diseases, clinical microbiology, clinical pharmacology, infection control, and guideline methodology experts jointly developed the present clinical practice guidelines based on best available scientific evidence to address the clinical issues regarding laboratory testing, antimicrobial therapy, and prevention of CRGNB infections. This guideline focuses on carbapenem-resistant Enterobacteriales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA). Sixteen clinical questions were proposed from the perspective of current clinical practice and translated into research questions using PICO (population, intervention, comparator, and outcomes) format to collect and synthesize relevant evidence to inform corresponding recommendations. The grading of recommendations, assessment, development and evaluation (GRADE) approach was used to evaluate the quality of evidence, benefit and risk profile of corresponding interventions and formulate recommendations or suggestions. Evidence extracted from systematic reviews and randomized controlled trials (RCTs) was considered preferentially for treatment-related clinical questions. Observational studies, non-controlled studies, and expert opinions were considered as supplementary evidence in the absence of RCTs. The strength of recommendations was classified as strong or conditional (weak). The evidence informing recommendations derives from studies worldwide, while the implementation suggestions combined the Chinese experience. The target audience of this guideline is clinician and related professionals involved in management of infectious diseases.
AB - The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group covering clinical infectious diseases, clinical microbiology, clinical pharmacology, infection control, and guideline methodology experts jointly developed the present clinical practice guidelines based on best available scientific evidence to address the clinical issues regarding laboratory testing, antimicrobial therapy, and prevention of CRGNB infections. This guideline focuses on carbapenem-resistant Enterobacteriales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA). Sixteen clinical questions were proposed from the perspective of current clinical practice and translated into research questions using PICO (population, intervention, comparator, and outcomes) format to collect and synthesize relevant evidence to inform corresponding recommendations. The grading of recommendations, assessment, development and evaluation (GRADE) approach was used to evaluate the quality of evidence, benefit and risk profile of corresponding interventions and formulate recommendations or suggestions. Evidence extracted from systematic reviews and randomized controlled trials (RCTs) was considered preferentially for treatment-related clinical questions. Observational studies, non-controlled studies, and expert opinions were considered as supplementary evidence in the absence of RCTs. The strength of recommendations was classified as strong or conditional (weak). The evidence informing recommendations derives from studies worldwide, while the implementation suggestions combined the Chinese experience. The target audience of this guideline is clinician and related professionals involved in management of infectious diseases.
KW - Antimicrobial susceptibility testing
KW - Antimicrobial therapy
KW - Carbapenem-resistant Pseudomonas aeruginosa
KW - Carbapenem-resistant enterobacteriales
KW - Carbapenem-resistant gram-negative bacillus
KW - Infection control
UR - http://www.scopus.com/inward/record.url?scp=85149815005&partnerID=8YFLogxK
U2 - 10.1016/j.jmii.2023.01.017
DO - 10.1016/j.jmii.2023.01.017
M3 - Review article
C2 - 36868960
AN - SCOPUS:85149815005
SN - 1684-1182
VL - 56
SP - 653
EP - 671
JO - Journal of Microbiology, Immunology and Infection
JF - Journal of Microbiology, Immunology and Infection
IS - 4
ER -